Citations

Clear

7 citation(s) found for "Stevens, Worta McCaskill".

Increasing Racial and Ethnic Equity, Diversity, and Inclusion in Cancer Treatment Trials: Evaluation of an ASCO-Association of Community Cancer Centers Site Self-Assessment
Guerra, Carmen E. , Pressman, Alice , Hurley, Patricia A. , Garrett‐Mayer, Elizabeth , Bruinooge, Suanna S. , Howson, A. G. , Kaltenbaugh, Melinda , Williams, Jen Hanley, Boehmer, Leigh , Bernick, Lea Ann, Byatt, Leslie, Crews, Jennie R. , McCaskill‐Stevens, Worta , Merrill, Janette K. , Nowakowski, Greg, Patel, Manali I. , Zwicker, Victoria, Oyer, Randall A. , Pierce, Lori J. , Guerra, Carmen E , Hurley, Patricia , Howson, Alexandra , Hanley Williams, Jen , Charlot, Marjory , Merrill, Janette , Nowakowski, Grzegorz S , Patel, Manali I , Ramirez, Amelie G , Oyer, Randall A , Bruinooge, Suanna Steeby , Garrett-Mayer, Elizabeth , Charlot, Marjory , Fashoyin-Aje, Lola

Mayo Clinic

JCO Oncology Practice | January 11, 2023 | Volume: 19 | Issue: 4 | Pages: e581-e588

10.1200/op.22.00560 | PMID 36630663 Get It

Clinical trial participants do not reflect the racial and ethnic diversity of people with cancer. ASCO and the Association of Community Cancer Centers collaborated on a quality improvement study to enhance racial and ethnic equity, diversity, and inclusion (EDI) in cancer clinical trials. The groups conducted a pilot study to examine the feasibility, utility, and face validity of a two-part clinical trial site self-assessment to enable diverse types of research sites in the United States to (1) review internal data to assess racial and ethnic disparities in screening and enrollment and (2) review their policies, programs, procedures to identify opportunities and strategies to improve EDI. Overall, 81% of 62 participating sites were satisfied with the assessment; 82% identified opportunities for improvement; and 63% identified specific strategies and 74% thought the assessment had potential to help their site increase EDI. The assessment increased awareness about performance (82%) and helped identify specific strategies (63%) to increase EDI in trials. Although most sites (65%) were able to provide some data on the number of patients that consented, only two sites were able to provide all requested trial screening, offering, and enrollment data by race and ethnicity. Documenting and evaluating such data are critical steps toward improving EDI and are key to identifying and addressing disparities more broadly. ASCO and Association of Community Cancer Centers will partner with sites to better understand their processes and the feasibility of collecting screening, offering, and enrollment data in systematic and automated ways.
Availability of data for screening, offering, and consenting patients to cancer clinical trials: Report from an ASCO-ACCC collaboration.
Pressman, Alice , Hurley, Patricia A. , Kaltenbaugh, Melinda , Bernick, Lea Ann, Byatt, Leslie, Crews, Jennie R. , McCaskill-Stevens, Worta J., Nowakowski, Grzegorz S. , Oyer, Randall A. , Patel, Manali I. , Pierce, Lori J. , Williams, Jen Hanley, Zwicker, Victoria, Hurley, Patricia , Bruinooge, Suanna S. , Garrett‐Mayer, Elizabeth , Boehmer, Leigh , Charlot, Marjory , Fashoyin-Aje, Lola , Ramirez, Amelie G , Guerra, Carmen E.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 6530-6530

10.1200/jco.2022.40.16_suppl.6530 Get It

6530 Background: Only a small fraction of patients with cancer participate in treatment trials. Patients identifying as members of racial and ethnic minority groups are consistently underrepresented in these trials. A recent systematic review reported that patients, regardless of race and ethnicity, are willing to enroll in trials if asked to participate by their treating clinician. Prospective and longitudinal data and metrics at the site- and clinician-level are necessary to understand whether patients are equitably considered for clinical trials. Methods: ASCO and Association of Community Cancer Centers (ACCC) developed a self-assessment for trial sites to record and gauge the number of patients across races and ethnicities screened, offered, and enrolled into clinical trials. Research sites, from across the US, were recruited through an open call to apply to participate in the ASCO-ACCC Pilot Project. There were 65 sites assigned to this pilot study, which tested the feasibility and utility of the site assessment. Sites were asked to enter 2019 and 2020 aggregate data for each step along the clinical trial enrollment continuum by select races and ethnicities (Black, Hispanic/Latinx, White) and overall. Results: 62 of 65 sites completed the study and represented a range of settings and practice types (61% academic, 26% hospital/health system, 13% independent). Only 2 sites (3%) were able to provide the data requested at each enrollment step in the assessment (table). Sites that collected the data did not do so routinely (table) and most had to compile data through multiple sources and/or manual extraction (40-100% across enrollment steps). Sites with missing data reported they did not collect data at all (36-64% across enrollment steps), did not collect data in a systematic way (0-29% across enrollment steps), or stated it would be too burdensome to manually review charts to extract data (12-29% across enrollment steps). Conclusions: Data collection and routine evaluation of participation metrics, by race and ethnicity, are necessary to assess and monitor equity and diversity in clinical trials. Most sites in this study did not collect, or routinely collect, data for screening, offering, and consenting patients to clinical trials. Without these data, sites are unable to evaluate and monitor whether their patients have equitable access to clinical trials or establish strategies to address any inequities. ASCO and ACCC will continue to partner with sites to better understand their processes and the feasibility of collecting such data in a systematic and automated way, such as through electronic health record systems. [Table: see text]
Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement
Oyer, Randall A. , Hurley, Patricia A. , Boehmer, Leigh , Bruinooge, Suanna S. , Levit, Kathryn , Barrett, Nadine J. , Benson, Al B. , Bernick, Lea Ann, Byatt, Leslie, Charlot, Marjory , Crews, Jennie R. , DeLeon, Kyle, Green, Sybil, Guerra, Carmen E. , Hamroun, Leila, Hardy, Claudia M. , Hempstead, Bridgette, Jeames, Sanford , Mann, Mel , Matin, Khalid , McCaskill‐Stevens, Worta , Merrill, Janette K. , Nowakowski, Grzegorz S. , Patel, Manali I. , Pressman, Alice , Segura, Juanita, Segarra-Vasquez, Barbara, Williams, Jen Hanley, Williams, J.E. Caerwyn , Winkfield, Karen M. , Yang, Eddy S. , Zwicker, Victoria, Pierce, Lori J. , Hurley, Patricia , Bruinooge, Suanna Steeby , Barrett, Nadine , Benson, Al , Fashoyin-Aje, Lola , Garrett-Mayer, Elizabeth , Gralow, Julie R , Guerra, Carmen E , Jeames, Sanford , Mann, Mel , Merrill, Janette , Nowakowski, Grzegorz S , Patel, Manali I , Pressman, Alice , Ramirez, Amelie G , Hanley Williams, Jen , Williams, James E , Winkfield, Karen M , Yang, Eddy S , Pierce, Lori J , Charlot, Marjory , Oyer, Randall A , Garrett‐Mayer, Elizabeth , Gralow, Julie R. , Segarra-Vasquez, Barbara

Mayo Clinic

Journal of Clinical Oncology | May 19, 2022 | Volume: 40 | Issue: 19 | Pages: 2163-2171

10.1200/jco.22.00754 | PMID 35588469 Get It

A concerted commitment across research stakeholders is necessary to increase equity, diversity, and inclusion (EDI) and address barriers to cancer clinical trial recruitment and participation. Racial and ethnic diversity among trial participants is key to understanding intrinsic and extrinsic factors that may affect patient response to cancer treatments. This ASCO and Association of Community Cancer Centers (ACCC) Research Statement presents specific recommendations and strategies for the research community to improve EDI in cancer clinical trials. There are six overarching recommendations: (1) clinical trials are an integral component of high-quality cancer care, and every person with cancer should have the opportunity to participate; (2) trial sponsors and investigators should design and implement trials with a focus on reducing barriers and enhancing EDI, and work with sites to conduct trials in ways that increase participation of under-represented populations; (3) trial sponsors, researchers, and sites should form long-standing partnerships with patients, patient advocacy groups, and community leaders and groups; (4) anyone designing or conducting trials should complete recurring education, training, and evaluation to demonstrate and maintain cross-cultural competencies, mitigation of bias, effective communication, and a commitment to achieving EDI; (5) research stakeholders should invest in programs and policies that increase EDI in trials and in the research workforce; and (6) research stakeholders should collect and publish aggregate data on racial and ethnic diversity of trial participants when reporting results of trials, programs, and interventions to increase EDI. The recommendations are intended to serve as a guide for the research community to improve participation rates among people from racial and ethnic minority populations historically under-represented in cancer clinical trials. ASCO and ACCC will work at all levels to advance the recommendations in this publication.
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx
Whelan, Timothy J. , Garcia, Sofia F. , Yanez, Betina R. , Carlos, Ruth C. , Albain, Kathy S. , Hayes, Daniel F. , Dees, Elizabeth Claire , McCaskill-Stevens, Worta J., Minasian, Lori M. , Cella, David , Garcia, Sofia F , Wagner, Lynne I. , Gray, Robert J. , Sparano, Joseph A. , Tevaarwerk, Amyé , Olson, John A. , Goetz, Matthew P. , Pritchard, Kathleen I. , Geyer, Charles E. , Sledge, George W. , Whelan, Timothy J

Mayo Clinic

Journal of Clinical Oncology | April 9, 2020 | Volume: 38 | Issue: 17 | Pages: 1875-1886

10.1200/jco.19.01866 | PMID 32271671 Get It

PURPOSE Cancer-related cognitive impairment (CRCI) is common during adjuvant chemotherapy and may persist. TAILORx provided a novel opportunity to prospectively assess patient-reported cognitive impairment among women with early breast cancer who were randomly assigned to chemoendocrine therapy (CT+E) versus endocrine therapy alone (E), allowing us to quantify the unique contribution of chemotherapy to CRCI. METHODS Women with a 21-gene recurrence score of 11 to 25 enrolled in TAILORX were randomly assigned to CT+E or E. Cognitive impairment was assessed among a subgroup of 552 evaluable women using the 37-item Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) questionnaire, administered at baseline, 3, 6, 12, 24, and 36 months. The FACT-Cog included the 20-item Perceived Cognitive Impairment (PCI) scale, our primary end point. Clinically meaningful changes were defined a priori and linear regression was used to model PCI scores on baseline PCI, treatment, and other factors. RESULTS FACT-Cog PCI scores were significantly lower, indicating more impairment, at 3, 6, 12, 24, and 36 months compared with baseline for both groups. The magnitude of PCI change scores was greater for CT+E than E at 3 months, the prespecified primary trial end point, and at 6 months, but not at 12, 24, and 36 months. Tests of an interaction between menopausal status and treatment were nonsignificant. CONCLUSION Adjuvant CT+E is associated with significantly greater CRCI compared with E at 3 and 6 months. These differences abated over time, with no significant differences observed at 12 months and beyond. These findings indicate that chemotherapy produces early, but not sustained, cognitive impairment relative to E, providing reassurance to patients and clinicians in whom adjuvant chemotherapy is indicated to reduce recurrence risk.
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Gray, Robert J. , Chen, Alice P. , Patton, David R. , Mitchell, Edith P. , Iafrate, A. John , Sklar, Jeffrey , Harris, Lyndsay N. , Rubinstein, Larry , Routbort, Mark, Coffey, Brent , Fu, Tony, Little, Richard F. , Marinucci, Donna M. , Catalano, Robert B., Magnan, Rick, Kibbe, Warren A. , Weil, Carol J. , Tricoli, James V. , Kumar, Shaji , Lih, Chih‐Jian, McCaskill‐Stevens, Worta , Takebe, Naoko, Datta, Vivekananda, Arteaga, Carlos L. , Abrams, Jeffrey S. , Comis, Robert L., O’Dwyer, Peter J , Conley, Barbara A. , Team, for the NCI-MATCH, Gray, Robert J , Patton, David R , Flaherty, Keith T. , Li, Shuli , Hamilton, Stanley R. , Williams, P. Mickey , McShane, Lisa M. , Sims, David J, Zwiebel, James A. , Alexander, Brian M. , Schwartz, Gary K. , Meric‐Bernstam, Funda , Caimi, Paolo F. , Takebe, Naoko , O’Dwyer, Peter J. , Team, for the NCI-MATCH, Rubinstein, Larry V

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 6, 2020 | Volume: 112 | Issue: 10 | Pages: 1021-1029

10.1093/jnci/djz245 | PMID 31922567 Get It

Abstract Background The proportion of tumors of various histologies that may respond to drugs targeted to molecular alterations is unknown. NCI-MATCH, a collaboration between ECOG-ACRIN Cancer Research Group and the National Cancer Institute, was initiated to find efficacy signals by matching patients with refractory malignancies to treatment targeted to potential tumor molecular drivers regardless of cancer histology. Methods Trial development required assumptions about molecular target prevalence, accrual rates, treatment eligibility, and enrollment rates as well as consideration of logistical requirements. Central tumor profiling was performed with an investigational next-generation DNA–targeted sequencing assay of alterations in 143 genes, and protein expression of protein expression of phosphatase and tensin homolog, mutL homolog 1, mutS homolog 2, and RB transcriptional corepressor 1. Treatments were allocated with a validated computational platform (MATCHBOX). A preplanned interim analysis evaluated assumptions and feasibility in this novel trial. Results At interim analysis, accrual was robust, tumor biopsies were safe (<1% severe events), and profiling success was 87.3%. Actionable molecular alteration frequency met expectations, but assignment and enrollment lagged due to histology exclusions and mismatch of resources to demand. To address this lag, we revised estimates of mutation frequencies, increased screening sample size, added treatments, and improved assay throughput and efficiency (93.9% completion and 14-day turnaround). Conclusions The experiences in the design and implementation of the NCI-MATCH trial suggest that profiling from fresh tumor biopsies and assigning treatment can be performed efficiently in a large national network trial. The success of such trials necessitates a broad screening approach and many treatment options easily accessible to patients.
The National Cancer Institute Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy
Kleckner, Ian R. , Barton, Debra L. , Mustian, Karen M. , O’Mara, Ann M., Germain, Diane St. , Cavaletti, Guido , Danhauer, Suzanne C. , Hopkins, Judith O. , Kelly, Katherine Patterson , Loprinzi, Charles L. , McLeod, Howard L. , Mohile, Supriya G. , Rowland, Julia H. , Salvemini, Daniela, Segal, Rosalind A. , Stevens, Worta McCaskill, Janelsins, Michelle C. , Dorsey, Susan G. , Hershman, Dawn L. , Hohmann, Andrea G. , Höke, Ahmet , Paice, Judith A. , Lavoie Smith, Ellen M , McCaskill‐Stevens, Worta

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 26, 2019 | Volume: 111 | Issue: 6 | Pages: 531-537

10.1093/jnci/djz011 | PMID 30715378 Get It

Abstract Although recent scientific advances have improved our understanding of basic biological mechanisms underlying chemotherapy-induced peripheral neuropathy (CIPN), few interventions are available to prevent or treat CIPN. Although some biological targets from preclinical studies show promise in nonhuman animal models, few targets have been translated to successful clinical trials. To address this problem, the National Cancer Institute’s Symptom Management and Health-Related Quality of Life Steering Committee convened a meeting of experts in the CIPN and oncology symptom management fields to participate in a Clinical Trials Planning Meeting (CTPM). Investigators presented data from preclinical and translational studies for possible CIPN interventions; these were evaluated for readiness of randomized clinical trial testing by experts, and recommendations were provided. Breakout sessions were convened to discuss and develop future studies. The CTPM experts concluded that there is compelling evidence to move forward with selected pharmacological and nonpharmacological clinical trials for the prevention and treatment of CIPN. Several key feasibility issues need to be addressed, however. These include identification of optimal outcome measures to define the CIPN phenotype, establishment of parameters that guide the evaluation of clinically meaningful effects, and adoption of approaches for inclusion of translational and biomarker and/or genetic measures. The results of the CTPM provide support for conducting clinical trials that include both pharmacological and nonpharmacological approaches, alone or in combination, with biomarkers, genetics, or other measures designed to inform underlying CIPN mechanisms. Several working groups were formed to design rigorous CIPN clinical trials, the results of which are ongoing.
Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).
Kottschade, Lisa A. , Halyard, Michele Y. , Sloan, Jeff A. , Flickinger, Lynn M. , Harris, Lyndsay N. , Le‐Lindqwister, Nguyet, Boyle, Frances , McCaskill-Stevens, Worta J., Zujewski, Jo Anne , Piccart, Martine , Perez, Edith A. , Dueck, Amylou C. , Hillman, David W. , Wolff, Antonio C. , Gralow, Julie R. , Pritchard, Kathleen I. , Ellard, Susan L. , Azambuja, Evandro de , Zujewski, Jo Anne

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 647-647

10.1200/jco.2014.32.15_suppl.647 Get It